CN1852739A - 包含二膦酸类的药物产品 - Google Patents

包含二膦酸类的药物产品 Download PDF

Info

Publication number
CN1852739A
CN1852739A CNA2004800269883A CN200480026988A CN1852739A CN 1852739 A CN1852739 A CN 1852739A CN A2004800269883 A CNA2004800269883 A CN A2004800269883A CN 200480026988 A CN200480026988 A CN 200480026988A CN 1852739 A CN1852739 A CN 1852739A
Authority
CN
China
Prior art keywords
product
container
bisphosphonates
solution
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800269883A
Other languages
English (en)
Chinese (zh)
Inventor
A·格劳施
R·勒夫勒
J·西格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34312464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1852739(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1852739A publication Critical patent/CN1852739A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CNA2004800269883A 2003-09-18 2004-09-17 包含二膦酸类的药物产品 Pending CN1852739A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50440203P 2003-09-18 2003-09-18
US60/504,402 2003-09-18

Publications (1)

Publication Number Publication Date
CN1852739A true CN1852739A (zh) 2006-10-25

Family

ID=34312464

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800269883A Pending CN1852739A (zh) 2003-09-18 2004-09-17 包含二膦酸类的药物产品

Country Status (23)

Country Link
US (1) US7932241B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663314A2 (cg-RX-API-DMAC7.html)
JP (1) JP4802096B2 (cg-RX-API-DMAC7.html)
KR (1) KR101015718B1 (cg-RX-API-DMAC7.html)
CN (1) CN1852739A (cg-RX-API-DMAC7.html)
AR (1) AR045670A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004271731B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414562A (cg-RX-API-DMAC7.html)
CA (1) CA2536206C (cg-RX-API-DMAC7.html)
CO (1) CO5680461A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP066419A (cg-RX-API-DMAC7.html)
IL (1) IL173766A (cg-RX-API-DMAC7.html)
IS (1) IS8351A (cg-RX-API-DMAC7.html)
MA (1) MA28078A1 (cg-RX-API-DMAC7.html)
MY (1) MY141763A (cg-RX-API-DMAC7.html)
NO (1) NO20061682L (cg-RX-API-DMAC7.html)
NZ (1) NZ545343A (cg-RX-API-DMAC7.html)
PE (1) PE20050468A1 (cg-RX-API-DMAC7.html)
RU (1) RU2358739C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN06084A1 (cg-RX-API-DMAC7.html)
TW (1) TWI345977B (cg-RX-API-DMAC7.html)
WO (1) WO2005025551A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200601209B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104721132A (zh) * 2013-12-21 2015-06-24 石药集团恩必普药业有限公司 一种唑来膦酸注射液及其制备方法
CN105232451A (zh) * 2015-09-27 2016-01-13 董贵雨 一种含有唑来膦酸的注射用组合物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
MY141763A (en) 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
EP1923049A1 (en) * 2006-11-17 2008-05-21 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
EP2088996A1 (en) * 2006-11-17 2009-08-19 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
ES2666650T3 (es) * 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
JP5607408B2 (ja) * 2009-04-03 2014-10-15 帝人ファーマ株式会社 アレンドロン酸含有注射剤
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
SI2459176T1 (en) * 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
EP2363111A1 (en) 2010-03-01 2011-09-07 Combino Pharm, S.L. Stable pharmaceutical composition comprising bisphosphonate
WO2011132826A1 (en) * 2010-04-19 2011-10-27 Snu R&Db Foundation Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2712611A1 (en) 2012-09-27 2014-04-02 B. Braun Melsungen AG Stabilized aqueous compositions of neuromuscular blocking agents
RU2506085C1 (ru) * 2013-01-30 2014-02-10 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
HK1258361A1 (zh) 2016-02-09 2019-11-08 太阳医药工业有限公司 灌注系统
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
AU2018342135A1 (en) * 2017-08-28 2020-04-16 Asdera Llc Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
CN110161168B (zh) * 2018-02-12 2022-12-20 四川科伦药物研究院有限公司 唑来膦酸及其杂质的高效液相色谱检测方法
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JP3672342B2 (ja) * 1994-09-26 2005-07-20 アステラス製薬株式会社 ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
GB0012209D0 (en) * 2000-05-19 2000-07-12 Novartis Ag Organic compounds
EP1671638A1 (en) * 2000-09-18 2006-06-21 F H Faulding & Co. Limited Disphosphonate solutions
BR0209361A (pt) * 2001-05-02 2004-06-08 Sicor Inc Dissódio de pamidronato injetável
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
MY141763A (en) 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104721132A (zh) * 2013-12-21 2015-06-24 石药集团恩必普药业有限公司 一种唑来膦酸注射液及其制备方法
CN104721132B (zh) * 2013-12-21 2018-05-18 石药集团恩必普药业有限公司 一种唑来膦酸注射液及其制备方法
CN105232451A (zh) * 2015-09-27 2016-01-13 董贵雨 一种含有唑来膦酸的注射用组合物
CN108261393A (zh) * 2015-09-27 2018-07-10 董贵雨 一种含有唑来膦酸的注射用药物组合物
CN105232451B (zh) * 2015-09-27 2019-02-05 青岛斯蒂朗机电设备有限公司 一种含有唑来膦酸的注射用组合物
CN108261393B (zh) * 2015-09-27 2020-10-27 山东则正医药技术有限公司 一种含有唑来膦酸的注射用药物组合物

Also Published As

Publication number Publication date
WO2005025551A2 (en) 2005-03-24
JP2007505861A (ja) 2007-03-15
KR101015718B1 (ko) 2011-02-22
NO20061682L (no) 2006-06-14
ZA200601209B (en) 2007-04-25
US7932241B2 (en) 2011-04-26
MY141763A (en) 2010-06-30
EP1663314A2 (en) 2006-06-07
BRPI0414562A (pt) 2006-11-07
ECSP066419A (es) 2006-09-18
NZ545343A (en) 2010-08-27
RU2358739C2 (ru) 2009-06-20
CA2536206C (en) 2010-08-24
CO5680461A2 (es) 2006-09-29
TW200522969A (en) 2005-07-16
AU2004271731A1 (en) 2005-03-24
JP4802096B2 (ja) 2011-10-26
AR045670A1 (es) 2005-11-02
KR20060087568A (ko) 2006-08-02
IL173766A (en) 2012-10-31
AU2004271731B2 (en) 2008-07-24
IS8351A (is) 2006-03-13
US20070015736A1 (en) 2007-01-18
IL173766A0 (en) 2006-07-05
MA28078A1 (fr) 2006-08-01
TWI345977B (en) 2011-08-01
TNSN06084A1 (en) 2007-10-03
CA2536206A1 (en) 2005-03-24
WO2005025551A3 (en) 2006-01-12
RU2006112596A (ru) 2007-11-10
PE20050468A1 (es) 2005-10-03

Similar Documents

Publication Publication Date Title
CN1852739A (zh) 包含二膦酸类的药物产品
US20080254089A1 (en) Pharmaceutical products comprising bisphosphonates
CN1277545C (zh) 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途
TWI871502B (zh) 高濃度抗體製劑
KR100889090B1 (ko) 에스몰올 제제
CN1535152A (zh) 二膦酸类化合物在治疗疼痛方面的应用
EP1284754B1 (en) Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
CN105960240A (zh) 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物
RU2286774C2 (ru) Препарат эсмолола
US20200188478A1 (en) Pre-mixed, ready to use vancomycin compositions
WO2014083580A2 (en) Pharmaceutical compositions of regadenoson
US20130040915A1 (en) Pharmaceutical composition
HK1214531A1 (zh) 稳定的静脉内制剂
US20040147486A1 (en) Liquid injectable formulation of disodium pamidronate
MXPA06003126A (en) Pharmaceutical products comprising bisphosphonates
US20240238275A1 (en) Hydromorphone formulations for multi-dose products
KR20120121403A (ko) 디포스포네이트 주사액 의약품 및 그 제법
RU2725962C2 (ru) Способ приготовления фармацевтической композиции на основе золедроновой кислоты в виде раствора для инфузий для лечения онкологических заболеваний и способ получения фармацевтической композиции на основе золедроновой кислоты в виде концентрата для приготовления раствора для инфузий для лечения онкологических заболеваний
US20060217350A1 (en) Disodium pamidronate formulation
HK1080711B (en) Use of bisphosphonates for the munufacture of a medicament for the treatment of bone metastasis associated with prostate cancer
HK1068550A (en) Use of bisphosphonates for pain treatment
HK1085129A (en) Liquid stable composition of oxazaphosphorine with mesna

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061025